LEADER 05096nam 2201381z- 450 001 9910674370003321 005 20231214132952.0 035 $a(CKB)5680000000037538 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81000 035 $a(EXLCZ)995680000000037538 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCancer Biomarker Research and Personalized Medicine 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (428 p.) 311 $a3-0365-3918-2 311 $a3-0365-3917-4 330 $aBiomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field of oncology is perhaps where it is most easily employed. Cancer is a heterogeneous disease; although patients may be diagnosed histologically with the same cancer type, their tumors can comprise varying tumor microenvironments and molecular characteristics that can impact treatment response and prognosis. There has been a major drive over the past decade to try and realize personalized cancer medicine through the discovery and use of disease-specific biomarkers. This book, entitled ?Cancer Biomarker Research and Personalized Medicine?, encompasses 22 publications from colleagues working on a diverse range of cancers, including prostate, breast, ovarian, head and neck, liver, gastric, bladder, colorectal, and kidney. The biomarkers assessed in these studies include genes, intracellular or secreted proteins, exosomes, DNA, RNA, miRNA, circulating tumor cells, circulating immune cells, in addition to radiomic features. 606 $aMedicine$2bicssc 606 $aOncology$2bicssc 610 $aclear cell renal cell carcinoma 610 $aradiomics 610 $aWHO/ISUP nuclear grade 610 $amultiphasic multidetector computed tomography 610 $atriple-negative breast cancer 610 $ataxane 610 $achemotherapy 610 $aGBP5 610 $aAkt/mTOR 610 $aautophagy 610 $aIL13R?2 610 $arenal cell carcinoma 610 $aJAK2 610 $aFOXO3 610 $atelmisartan 610 $aovarian cancer 610 $abioinformatics 610 $aCREB1 610 $adrug perturbation 610 $alincRNA-p21 610 $arectal cancer 610 $achemoradiotherapy 610 $acolorectal cancer 610 $along non-coding RNA 610 $ap53 610 $apredictive biomarker 610 $aintestinal anastomosis 610 $aanastomotic leak 610 $abiomarkers 610 $aprecision medicine 610 $apersonalized medicine 610 $abiomarker 610 $aAmpliSeq 610 $aDNA methylation 610 $aepigenetics 610 $ahead and neck cancer 610 $asaliva 610 $aliquid biopsy 610 $ameta-analysis 610 $agastric cancer 610 $amiddle-up-down 610 $ahaptoglobin 610 $aglycopeptide 610 $amass spectrometry 610 $acirculating tumor cells 610 $aprostate cancer 610 $acancer vaccine 610 $aimmune response 610 $abreast cancer 610 $apredictive tools 610 $aprognostic tools 610 $atranslational research 610 $aIL6ST 610 $agp130 610 $acytokine signalling 610 $atissue-based biomarkers 610 $aliquid-based biomarkers 610 $aradiotherapy 610 $aradiosensitivity biomarkers 610 $asecretome 610 $aradioresistance 610 $abladder tumor 610 $alymphocyte-to-monocyte ratio 610 $aperipheral blood parameters 610 $atumor recurrence 610 $atransurethral resection 610 $alipidomics 610 $a1H-NMR 610 $aLC-MS/MS 610 $alipoprotein subfractions 610 $alipoprotein lipase 610 $acancer biomarkers 610 $ahepatocellular carcinoma 610 $ap16 expression 610 $ahead and neck squamous cell carcinoma 610 $aHPV genotyping 610 $aexosomes 610 $achemoresistance 610 $acomparative oncology 610 $aOne Health 610 $amicroRNA 610 $alymph node metastasis 610 $ahormone-dependent carcinogenesis 610 $alocalized prostate cancer 610 $aprognostic factors 610 $aHNSCC 615 7$aMedicine 615 7$aOncology 700 $aMeehan$b James$4edt$01338657 702 $aMeehan$b James$4oth 906 $aBOOK 912 $a9910674370003321 996 $aCancer Biomarker Research and Personalized Medicine$93058897 997 $aUNINA